{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:52:54Z","timestamp":1788349974199,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mirogabalin is a novel, preferentially selective \u03b1<jats:sub>2<\/jats:sub>\u03b4\u20101 ligand under investigation to treat neuropathic pain. The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of various doses of mirogabalin in healthy subjects of different ethnicities. This randomized, placebo\u2010controlled, double\u2010blind, sequential, ascending\u2010dose study evaluated single (10\u201040\u00a0mg) and repeated (10, 15\u00a0mg twice a day) doses of mirogabalin in Japanese subjects, and a single dose of mirogabalin in Korean, Chinese, and white subjects. Mirogabalin was rapidly absorbed, with a median time to maximum plasma concentration of 1\u00a0hour, and rapidly eliminated, with a mean elimination half\u2010life of 2 to 3\u00a0hours. Single\u2010dose mirogabalin pharmacokinetic parameters were comparable between Asian and white subjects. Exposure increased proportionally as mirogabalin dose increased in Japanese subjects. Mean mirogabalin steady\u2010state clearance and volume of distribution values were comparable across dose levels. No accumulation of mirogabalin was observed on repeated dosing in Japanese subjects. Mirogabalin had an acceptable safety and tolerability profile in Asian and white subjects at doses up to 15\u00a0mg twice a day for 7 days. The most common treatment\u2010emergent adverse events (somnolence, headache, and dizziness) were consistent with the known mechanism of action and safety profile of mirogabalin.<\/jats:p>","DOI":"10.1002\/cpdd.448","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T08:50:48Z","timestamp":1523955048000},"page":"661-669","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Randomized, Placebo\u2010Controlled, Double\u2010Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers"],"prefix":"10.1002","volume":"7","author":[{"given":"Mendel","family":"Jansen","sequence":"first","affiliation":[{"name":"Daiichi Sankyo Development Ltd  Gerrards Cross Buckinghamshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Warrington","sequence":"additional","affiliation":[{"name":"Hammersmith Medicines Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Dishy","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Pharma Development  Basking Ridge NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Ohwada","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co.Ltd.  Hiromachi, Shinagawa\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Johnson","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Development Ltd  Gerrards Cross Buckinghamshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Brown","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Pharma Development  Basking Ridge NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co.Ltd.  Hiromachi, Shinagawa\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"issue":"10","key":"e_1_2_7_2_1","article-title":"Pharmacological, pharmacokinetics and safety profiles of DS\u20105565, a novel \u03b12\u03b4 ligand (P7.301)","volume":"82","author":"Yokoyama T DY","year":"2014","journal-title":"Neurology"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0356-09.2009"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1964"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409066103"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.10.5768"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.01.382"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2016.1202764"},{"issue":"2","key":"e_1_2_7_9_1","first-page":"57","article-title":"Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin","volume":"58","author":"Yin OQ","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.974"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1044"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.567"},{"issue":"10","key":"e_1_2_7_13_1","first-page":"1443","article-title":"A multiple ascending\u2010dose study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy elderly subjects","volume":"67","author":"Brown K","year":"2015","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.141"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02282.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0172-7"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-197910000-00004"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1037\/1040-3590.17.2.237"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-015-0207-7"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22681"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T17:04:36Z","timestamp":1694279076000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1002\/cpdd.448"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.448","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"2017-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}